Journal of Global Antimicrobial Resistance (Mar 2020)

Use of colistin in adult patients: A cross-sectional study

  • Daniele Roberto Giacobbe,
  • Carolina Saffioti,
  • Angela Raffaella Losito,
  • Matteo Rinaldi,
  • Caterina Aurilio,
  • Cesare Bolla,
  • Silvia Boni,
  • Guglielmo Borgia,
  • Novella Carannante,
  • Giovanni Cassola,
  • Giancarlo Ceccarelli,
  • Silvia Corcione,
  • Daniela Dalla Gasperina,
  • Francesco Giuseppe De Rosa,
  • Chiara Dentone,
  • Stefano Di Bella,
  • Nicoletta Di Lauria,
  • Marcello Feasi,
  • Marco Fiore,
  • Sara Fossati,
  • Erica Franceschini,
  • Andrea Gori,
  • Guido Granata,
  • Sara Grignolo,
  • Paolo Antonio Grossi,
  • Giuliana Guadagnino,
  • Filippo Lagi,
  • Alberto Enrico Maraolo,
  • Valeria Marinò,
  • Maria Mazzitelli,
  • Alessandra Mularoni,
  • Alessandra Oliva,
  • Maria Caterina Pace,
  • Andrea Parisini,
  • Francesca Patti,
  • Nicola Petrosillo,
  • Vincenzo Pota,
  • Francesca Raffaelli,
  • Marianna Rossi,
  • Antonella Santoro,
  • Carlo Tascini,
  • Carlo Torti,
  • Enrico Maria Trecarichi,
  • Mario Venditti,
  • Pierluigi Viale,
  • Alessio Signori,
  • Matteo Bassetti,
  • Valerio Del Bono,
  • Maddalena Giannella,
  • Malgorzata Mikulska,
  • Mario Tumbarello,
  • Claudio Viscoli

Journal volume & issue
Vol. 20
pp. 43 – 49

Abstract

Read online

Objectives: The aim of this study was to assess colistin use in a country endemic for multidrug-resistant Gram-negative bacteria (MDR-GNB). Methods: Colistin prescription patterns were evaluated in 22 Italian centres. Factors associated with use of colistin in combination with other anti-MDR-GNB agents were also assessed. Results: A total of 221 adults receiving colistin were included in the study. Their median age was 64 years (interquartile range 52–73 years) and 134 (61%) were male. Colistin was mostly administered intravenously (203/221; 92%) and mainly for targeted therapy (168/221; 76%). The most frequent indications for colistin therapy were bloodstream infection and lower respiratory tract infection. Intravenous colistin was administered in combination with at least another anti-MDR-GNB agent in 80% of cases (163/203). A loading dose of 9 MU of colistimethate was administered in 79% of patients receiving i.v. colistin and adequate maintenance doses in 85%. In multivariable analysis, empirical therapy [odds ratio (OR) = 3.25, 95% confidence interval (CI) 1.24–8.53;P = 0.017] and targeted therapy for carbapenem-resistant Enterobacterales infection (OR = 4.76, 95% CI 1.69–13.43; P = 0.003) were associated with use of colistin in combination with other agents, whilst chronic renal failure (OR = 0.39, 95% CI 0.17–0.88; P = 0.024) was associated with use of colistin monotherapy. Conclusion: Colistin remains an important option for severe MDR-GNB infections when other treatments are not available. Despite inherent difficulties in optimising its use owing to peculiar pharmacokinetic/pharmacodynamic characteristics, colistin was mostly used appropriately in a country endemic for MDR-GNB.

Keywords